Amphastar Pharmaceuticals (AMPH) Competitors

Amphastar Pharmaceuticals (NASDAQ:AMPH) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Do analysts rate AMPH or ADMA?

Amphastar Pharmaceuticals currently has a consensus price target of $32.33, indicating a potential upside of 38.40%. ADMA Biologics has a consensus price target of $27.67, indicating a potential upside of 55.26%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Which has more risk & volatility, AMPH or ADMA?

Amphastar Pharmaceuticals has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Is AMPH or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to Amphastar Pharmaceuticals' net margin of 19.38%. ADMA Biologics' return on equity of 47.16% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	19.38%	22.20%	10.40%
ADMA Biologics	45.01%	47.16%	30.51%

Does the media refer more to AMPH or ADMA?

In the previous week, ADMA Biologics had 11 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 16 mentions for ADMA Biologics and 5 mentions for Amphastar Pharmaceuticals. ADMA Biologics' average media sentiment score of 0.87 beat Amphastar Pharmaceuticals' score of 0.44 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders believe in AMPH or ADMA?

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has better valuation & earnings, AMPH or ADMA?

ADMA Biologics has lower revenue, but higher earnings than Amphastar Pharmaceuticals. Amphastar Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$731.97M	1.50	$159.52M	$2.76	8.46
ADMA Biologics	$426.45M	9.98	$197.67M	$0.85	20.96

Summary

ADMA Biologics beats Amphastar Pharmaceuticals on 13 of the 17 factors compared between the two stocks.